Hannah Valantine Bridge Bio Pharma, Inc. (BBIO) insider trading activity

Hannah Valantine is of BridgeBio Pharma, Inc.. Currently has a direct ownership of 1,764 shares of BBIO, which is worth approximately $41,312. The most recent transaction as insider was on Feb 15, 2024, when has been sold 2,915 shares (Common Stock) at a price of $37.75 per share, resulting in proceeds of $110,041. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.76K

0% 3M change

0% 12M change

Total Value Held $41,312

Hannah Valantine Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 15 2024	SELL Open market or private sale	$110,041 $37.75 p/Share	2,915 Reduced 62.3%	1,764 Common Stock
Feb 15 2024	BUY Exercise of conversion of derivative security	$24,631 $8.45 p/Share	2,915 Added 38.39%	4,679 Common Stock
Jan 16 2024	SELL Open market or private sale	$110,682 $37.97 p/Share	2,915 Reduced 62.3%	1,764 Common Stock
Jan 16 2024	BUY Exercise of conversion of derivative security	$24,631 $8.45 p/Share	2,915 Added 38.39%	4,679 Common Stock
Dec 15 2023	SELL Open market or private sale	$105,289 $36.12 p/Share	2,915 Reduced 62.3%	1,764 Common Stock
Dec 15 2023	BUY Exercise of conversion of derivative security	$24,631 $8.45 p/Share	2,915 Added 38.39%	4,679 Common Stock
Nov 15 2023	SELL Open market or private sale	$87,450 $30.0 p/Share	2,915 Reduced 62.3%	1,764 Common Stock
Nov 15 2023	BUY Exercise of conversion of derivative security	$24,631 $8.45 p/Share	2,915 Added 38.39%	4,679 Common Stock
Dec 29 2021	BUY Open market or private purchase	$25,102 $14.23 p/Share	1,764 Added 50.0%	1,764 Common Stock

Also insider at

PACB

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Healthcare

Director

CDNA

CareDx, Inc. Healthcare